Introduction
============

Endometrial cancer, originating from the uterine epithelium, is the most common type of gynecological tumor in developed countries ([@b1-etm-0-0-8205]). It has been indicated that the vast majority of cases of endometrial cancer are not linked with familial inheritance ([@b2-etm-0-0-8205]). In the year 2016, \~60,050 new cases and 10,470 mortalities associated with endometrial cancer were reported in the USA ([@b3-etm-0-0-8205]). Furthermore, the incidence of endometrial cancer appears to be rapidly increasing in the USA ([@b4-etm-0-0-8205]). In addition, numerous previous studies have suggested that endometrial cancer has a higher incidence in developing countries ([@b5-etm-0-0-8205],[@b6-etm-0-0-8205]). For most patients newly diagnosed with endometrial cancer, the prognosis is good and the 5 year survival rate may be as high as 81.1% ([@b7-etm-0-0-8205]). Stage, grade, histological subtype, myometrial depth invasion and lymphovascular space involvement have been identified as major prognostic factors for endometrial cancer ([@b8-etm-0-0-8205],[@b9-etm-0-0-8205]).

In 1872, Riess *et al* ([@b10-etm-0-0-8205]) reported the association between elevated platelet counts and malignant tumors. To date, various studies have confirmed that pre-treatment thrombocytosis may be used as a prognostic indicator for patients with numerous solid tumor types, including lung, gastric, colorectal, esophageal, hepatocellular, pancreatic, breast and ovarian cancer, glioblastoma, renal cell carcinoma, oral squamous cell carcinoma, breast cancer and ovarian cancer ([@b11-etm-0-0-8205]--[@b22-etm-0-0-8205]). This effect may be due to the role served by platelets in tumor growth, angiogenesis and metastasis ([@b23-etm-0-0-8205]--[@b26-etm-0-0-8205]).

To date, whether pre-treatment thrombocytosis is able to predict the prognosis of patients with endometrial cancer remains unclear. To the best of our knowledge, no previous prospective randomized trials have been performed to evaluate the pre-treatment platelet count for predicting the prognosis for endometrial cancer. In addition, in a prior retrospective controlled trial investigating this association, the number of patients was limited ([@b27-etm-0-0-8205]). In the present study, a pooled analysis of a large number of patients was performed to investigate the effect of preoperative thrombocytopenia on the prognosis of endometrial carcinoma. The present study aimed to investigate the association between thrombocytosis and the prognosis of patients with endometrial cancer to provide a reference for clinical therapy.

Materials and methods
=====================

### Search for relevant studies

On December 17, 2018, studies associated with endometrial cancer and thrombocytosis were systematically searched for using the PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Embase (<https://www.embase.com>) and Cochrane Library databases (<http://www.cochranelibrary.com/>). In addition, references to relevant reviews were manually searched in order to avoid excluding any studies that met the selection criteria. The terms used for the search were as follows: i) 'Thrombocytosis', 'thrombocythemia' or 'platelet count'; and ii) 'endometrial cancer', 'endometrial neoplasm' or 'endometrial carcinoma'. Furthermore, the language was not limited during the search process. Two researchers independently searched for relevant studies and screened the articles according to the inclusion and exclusion criteria applied in the present study.

### Inclusion criteria

The inclusion criteria for the present study were as follows: i) The study covered the prognosis of endometrial cancer; ii) the study described the effects of thrombocytosis or platelet count on the prognosis of endometrial cancer; iii) the study contained relevant prognostic data, including hazard ratios (HR) and the corresponding 95% CI for overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) and disease-specific survival (DSS); iv) the relevant HR and corresponding 95% CI were available through conversion.

### Exclusion criteria

The following exclusion criteria were applied: i) Subjects did not have endometrial cancer; ii) the study did not include the platelet count or any information regarding thrombocytosis; iii) the study was a case report, review or meta-analysis; iv) required data were unavailable. In addition, studies that did not include any data on the prognosis of patients with endometrial cancer were also excluded.

### Data extraction and quality assessment

Two researchers extracted the data, including author, publication year, country, sample size, clinical stage, age, cut-off and follow-up time using a pre-made spreadsheet. In the present study, the effect of thrombocytosis on OS was used as the primary outcome, and the impact of thrombocytosis on PFS, DFS and DSS was considered as a secondary outcome. In the process of calculating the HR and its 95% CI, multivariate analyses were initially performed, followed by univariate analyses, and finally Kaplan-Meier survival curves. Kaplan-Meier survival curve analysis was performed using Engauge Digitizer 4.1 (<http://digitizer.sourceforge.net/>). For studies in which OR or 95% CI could not be obtained directly, OR and 95% CI were obtained through Kaplan-Meier survival analysis. A non-randomized study (NRS) rating scale was used to evaluate the quality of the studies included in the present meta-analysis, as previously described ([@b28-etm-0-0-8205]). If inconsistent results regarding literature searches and data extraction were identified between two researchers, a third researcher was consulted to resolve the discrepancy.

### Statistical analysis

Stata statistical software (version 13.0; StataCorp, LLC) was used to perform all statistical analyses and P\<0.05 was considered to indicate statistical significance. Cochran\'s Q and I^2^ tests were performed to quantify the heterogeneity of the HR. If the heterogeneity was \>50%, random-effects models were selected for pooled analysis; otherwise, a fixed-effects model was used. In addition, Egger\'s test was performed to assess the publication bias and sensitivity analysis was used to examine the effect of a single study on the final results.

Results
=======

### Search and screening of eligible studies

A total of 349 studies were initially identified by searching the PubMed, Embase and Cochrane Library databases and through manual searching. After exclusion of duplicate studies, 77 studies were retained. Subsequently, 64 articles comprising reviews, meta-analyses, case reports and studies investigating other tumor types were removed by analyzing the title and abstracts. The full text of the remaining 13 articles was then reviewed and two studies lacking sufficient data were excluded. Finally, 11 studies ([@b29-etm-0-0-8205]--[@b39-etm-0-0-8205]) met the inclusion criteria and were included in the meta-analysis. The process of study selection is illustrated in [Fig. 1](#f1-etm-0-0-8205){ref-type="fig"}.

### Basic characteristics of included studies

In order to understand the basic characteristics of the studies included, relevant data, including publication year, country, number of cases, age of the patients and platelet count, were extracted. Detailed basic information on the studies included is provided in [Table I](#tI-etm-0-0-8205){ref-type="table"}. In total, 3 of the 11 studies included in the present meta-analysis analyzed patients exhibiting tumors at stage III--IV and the remaining 8 examined patients with tumors at stage I--IV. These previous studies were published after 2000 and 5 were published after 2015. The study by Gorelick *et al* ([@b37-etm-0-0-8205]) analyzed platelet counts as continuous variables and the remaining studies analyzed platelet counts as categorical variables with corresponding cut-off values. In total, 9 of the 11 studies reported the effect of pre-treatment thrombocytosis on the OS of patients with endometrial cancer.

### Quality assessment

To measure the quality of the studies included, an NRS rating scale was applied. The results of the quality evaluation are provided in [Table II](#tII-etm-0-0-8205){ref-type="table"}. Among the 11 studies included in the present study, the baseline data of three studies were comparable and those of the other 8 studies were only partially comparable. In total, 4 studies did not control for confrontation factor. Finally, 4 articles had a quality score of 7 and the remaining studies had a score of \>7.

### Pooled analysis for OS

A total of 9 studies comprising 1,715 patients reported the effects of pre-treatment thrombocytosis on the OS of patients with endometrial cancer ([@b29-etm-0-0-8205]--[@b32-etm-0-0-8205],[@b34-etm-0-0-8205],[@b36-etm-0-0-8205]--[@b39-etm-0-0-8205]). Considering the large heterogeneity, a random-effects model was used to summarize the 9 articles (I^2^=81.7%; P\<0.001; [Fig. 2](#f2-etm-0-0-8205){ref-type="fig"}). The pooled analysis indicated that pre-treatment thrombocytosis was associated with a significantly reduced OS of patients with endometrial cancer (HR=2.25; 95% CI=1.26--4.00; P\<0.001; [Fig. 2](#f2-etm-0-0-8205){ref-type="fig"}), indicating that thrombocytosis may affect the prognosis of patients with endometrial cancer.

### Pooled analysis for PFS, DFS and DSS

To determine the effects of pre-treatment thrombocytosis on other prognostic indicators, PFS, DFS and DSS were also analyzed. Of the 11 studies included in the present meta-analysis, 8 studies included relevant data: 3 Studies reported on PFS, DFS and DSS ([@b32-etm-0-0-8205],[@b36-etm-0-0-8205],[@b37-etm-0-0-8205]), 3 on DFS ([@b30-etm-0-0-8205],[@b33-etm-0-0-8205],[@b34-etm-0-0-8205]) and 2 on DSS ([@b33-etm-0-0-8205],[@b35-etm-0-0-8205]). The pooled analysis indicated that pre-treatment thrombocytosis was significantly associated with PFS and DFS, but not with DSS (PFS, HR=2.60, 95% CI=1.23--5.50, P=0.013; DFS, HR=2.23, 95% CI=1.45--3.42, P\<0.001; DSS, HR=2.17, 95% CI=0.51--9.27, P=0.296; Supplemental [Figs. S1](#SD1-etm-0-0-8205){ref-type="supplementary-material"}--[S3](#SD1-etm-0-0-8205){ref-type="supplementary-material"}). The present results further confirmed that pre-treatment thrombocytosis may be used to predict the prognosis of patients with endometrial cancer.

### Subgroup analysis

To further examine the association between pre-treatment thrombocytosis and prognosis of endometrial cancer in different patients and studies, a subgroup analysis was performed based on publication date, the region covered by the study, the number of cases included in the analysis, the type of cancer included in analysis, whether it was a multivariate or single-factor analysis and the platelet count cut-off. Detailed results of the subgroup analyses are provided in [Table III](#tIII-etm-0-0-8205){ref-type="table"}. The publication date and the number of cases included in the analysis both had a significant effect on patient prognosis. The results indicated that pre-treatment thrombocytosis was not associated with OS in patients from Asia or Europe, however, there appeared to be some association for patients from America. Patients with uterine serous papillary carcinoma (USPC) and endometrial cancer were included in the study cohort. There was no association for USPC patients, but endometrial cancer patient prognosis was related to pre-operative thrombocytopenia. No association between pre-operative thrombocytopenia and prognosis was noted for patients with a platelet count of ≥350×10^9^/l, however, the total survival time of patients with a cut-off \>400 was related to pre-operative thrombocytopenia ([Table III](#tIII-etm-0-0-8205){ref-type="table"}).

### Publication bias and sensitivity analysis

In order to evaluate the potential publication bias, the articles included in the present meta-analysis were subjected to Egger\'s test. The results indicated no significant publication bias in the present study (P=0.565). A sensitivity analysis was also performed to assess the effect of a single study on the final results. The analysis suggested that the impact of individual studies on the results of the pooled analysis was negligible, indicating that the present conclusions are not influenced by individual articles and exhibit high robustness ([Fig. 3](#f3-etm-0-0-8205){ref-type="fig"}).

Discussion
==========

Identification of prognostic markers for patients with endometrial cancer is important and may facilitate clinical decisions regarding potential treatments and disease outcome. The present study performed a pooled analysis of the results of previously published studies to assess whether pre-treatment thrombocytosis may be a prognostic indicator for patients with endometrial cancer. The meta-analysis suggested that pre-treatment thrombocytosis was significantly associated with OS, PFS and DFS in patients with endometrial cancer, but was not significantly associated with DSS. Furthermore, quality assessments, publication bias analysis and sensitivity analysis of the studies included confirmed that the present results were reliable. Of note, only two previous studies reported an association between pre-treatment thrombocytosis and DSS ([@b33-etm-0-0-8205],[@b35-etm-0-0-8205]). Further studies with more patients are required in order to investigate the association between pre-treatment thrombocytosis and DSS.

Previous studies have reported that 7--41% of patients with endometrial cancer suffer from thrombocytosis with different cut-offs ([@b29-etm-0-0-8205],[@b34-etm-0-0-8205],[@b35-etm-0-0-8205],[@b37-etm-0-0-8205]--[@b44-etm-0-0-8205]). In addition, one previous study indicated a significant correlation between thrombocytosis and clinical stages, suggesting that patients with advanced clinical stage are more likely to suffer from thrombocytosis ([@b29-etm-0-0-8205]). Thrombocytosis may reduce the rate of chemotherapy response in patients with endometrial cancer, and this effect may explain why patients with thrombocytosis have a poor prognosis ([@b33-etm-0-0-8205]). A retrospective study by Borges *et al* ([@b45-etm-0-0-8205]) analyzed \~1,000 patients with lung cancer and indicated that a platelet count of \>440×10^3^/mm^3^ significantly reduced the chemotherapy response rate ([@b45-etm-0-0-8205]). Furthermore, a previous study suggested that an increase in the platelet count may reduce the resistance to docetaxel-induced apoptosis in a mouse model of ovarian cancer ([@b46-etm-0-0-8205]). In addition, previous studies suggested that thrombocytosis may increase the risk of thromboembolism in cancer patients ([@b35-etm-0-0-8205],[@b46-etm-0-0-8205]). The present study suggested that a platelet count of ≥400×10^3^/mm^3^ was significantly associated with a reduced OS of patients with endometrial cancer. Further studies are required to investigate the molecular mechanisms underlying the effect of thrombocytosis on the prognosis of patients with endometrial cancer.

A previous study demonstrated that various cytokines and growth factors, including thrombopoietin, interleukin-1 (IL-1), IL-3, IL-6, IL-11 and leukemia inhibitory factors are able to enhance platelet production ([@b23-etm-0-0-8205]). Elevated levels of IL-6 were previously identified to be associated with poor prognosis of patients with ovarian cancer ([@b47-etm-0-0-8205]). Various previous studies have indicated that thrombocytosis may be a paraneoplastic syndrome in patients with ovarian cancer, and thrombocytosis may stimulate angiogenesis and lead to tumor progression via increased secretion of IL-6 from tumor cells ([@b46-etm-0-0-8205],[@b48-etm-0-0-8205],[@b49-etm-0-0-8205]). Due to limited information provided by the studies included, the present study did not investigate the association between multiple growth factors and platelet formation in patients with endometrial cancer. Further studies are required to investigate whether IL-6 is involved in platelet formation in patients with endometrial cancer and IL-6 may be a novel potential therapeutic target for treating endometrial cancer, providing a novel direction for future studies. To the best of our knowledge, the present study was the first meta-analysis investigating the association between pre-treatment thrombocytosis and prognosis in patients with endometrial cancer. Pooled analysis of prognostic indicators for OS, PFS, DFS and DSS in patients with endometrial cancer was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@b50-etm-0-0-8205]) and reliable results were obtained. However, the present study has certain limitations. First, the analysis included a small number of studies on uterine serous papillary carcinoma and further studies are required to examine this type of tumor. In addition, the results of the present meta-analysis suggested that pre-treatment thrombocytosis was not associated with the prognosis of patients with endometrial cancer and a platelet count of ≥350×10^3^/mm^3^, and this result requires further investigation using a larger sample size. Furthermore, it is necessary to analyze the association between thrombocytosis and the prognosis of stage I--II endometrial cancer. This was not analyzed in the present study due to the lack of previous studies reporting on this.

The results of the present systematic review and meta-analysis indicated that pre-treatment thrombocytosis was significantly associated with OS in patients with endometrial cancer at stage III--IV. Furthermore, pre-treatment thrombocytosis (\>400×10^3^ platelets/mm^3^) was an independent predictor of OS regardless of the clinical stage. In addition, patients with pre-treatment thrombocytosis had poor DFS and PFS.
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###### 

Basic characteristics of the 11 studies included in the present meta-analysis.

  Author (year)      Country        Case number   FIGO stage   Age (years)                                                       Cut-off      Follow-up time^[a](#tfn1-etm-0-0-8205){ref-type="table-fn"}^ (months)   Category             Adjusted^[b](#tfn2-etm-0-0-8205){ref-type="table-fn"}^   Survival analysis                                       (Refs.)
  ------------------ -------------- ------------- ------------ ----------------------------------------------------------------- ------------ ----------------------------------------------------------------------- -------------------- -------------------------------------------------------- ------------------------------------------------------- -----------------------
  Takahashi (2017)   Japan          508           I--IV        58.0±10.5                                                         \>400,000    Unclear                                                                 Endometrial cancer   Yes                                                      OS                                                      ([@b29-etm-0-0-8205])
  Abu-Zaid (2017)    Saudi Arabia   162           I--IV        59.0±11.0                                                         \>400,000    Unclear                                                                 Endometrial cancer   Yes                                                      OS, DFS                                                 ([@b30-etm-0-0-8205])
  Younes (2016)      Israel         56            I--IV        69.4±15.0                                                         \>400,000    76.8                                                                    USPC                 No                                                       OS                                                      ([@b31-etm-0-0-8205])
  Nakamura (2016)    Japan          108           I--IV        60.0 (27.0--87.0)^[a](#tfn1-etm-0-0-8205){ref-type="table-fn"}^   ≥350,000     Unclear                                                                 Endometrial cancer   No                                                       OS, PFS                                                 ([@b32-etm-0-0-8205])
  Kizer (2015)       USA            318           I--IV        Unclear                                                           \>400,000    25.6/23.1                                                               Endometrial cancer   Yes                                                      DSS, DFS                                                ([@b33-etm-0-0-8205])
  Heng (2014)        Thailand       238           I--IV        57.9±10.0                                                         \>400,000    59.6 (1.0--98.0)                                                        Endometrial cancer   Yes                                                      OS, DFS                                                 ([@b34-etm-0-0-8205])
  Njølstad (2013)    Norway         557           I--IV        66.2±11.7                                                         \>390,000    55.0 (0.0--97.0)                                                        Endometrial cancer   No                                                       DSS                                                     ([@b35-etm-0-0-8205])
  Matsuo (2013)      USA            516           I--IV        52.0±10.4                                                         \>400,000    43.7                                                                    Endometrial cancer   No                                                       OS, PFS                                                 ([@b36-etm-0-0-8205])
  Gorelick (2009)    USA            29            III--IV      Unclear                                                           Continuous   Unclear                                                                 Endometrial cancer   Yes: OS No: PFS                                          OS, PFS^[c](#tfn3-etm-0-0-8205){ref-type="table-fn"}^   ([@b37-etm-0-0-8205])
  Lerner (2007)      USA            39            III--IV      Unclear                                                           \>400,000    Unclear                                                                 USPC                 Yes: OS                                                  OS                                                      ([@b38-etm-0-0-8205])
  Scholz (2000)      Turkey         59            III--IV      64.8                                                              \>400,000    Unclear                                                                 Endometrial cancer   No                                                       OS^[c](#tfn3-etm-0-0-8205){ref-type="table-fn"}^        ([@b39-etm-0-0-8205])

Median (range).

Adjusted: Data from multivariate analysis with Cox proportional hazards regression model

Data from survival curve. FIGO, International Federation of Gynecologists and Obstetricians; OS, overall survival; DFS, disease-free survival; DSS, disease-specific survival; PFS, progression-free survival; USPC, uterine serous papillary carcinoma.

###### 

Quality evaluation results of 11 studies included in the present meta-analysis.

  Study              Grouping method   Blinding   ITT   Baseline data   Diagnostic criteria   Confrontation factor control   Quality level^[a](#tfn5-etm-0-0-8205){ref-type="table-fn"}^   (Refs.)
  ------------------ ----------------- ---------- ----- --------------- --------------------- ------------------------------ ------------------------------------------------------------- -----------------------
  Takahashi (2017)   2                 0          2     2               2                     2                              10                                                            ([@b29-etm-0-0-8205])
  Abu-Zaid (2017)    2                 0          2     1               2                     2                              9                                                             ([@b30-etm-0-0-8205])
  Younes (2016)      2                 0          2     1               2                     0                              7                                                             ([@b31-etm-0-0-8205])
  Nakamura (2016)    2                 0          2     1               2                     0                              7                                                             ([@b32-etm-0-0-8205])
  Kizer (2015)       2                 0          2     2               2                     2                              10                                                            ([@b33-etm-0-0-8205])
  Heng (2014)        2                 0          2     1               2                     2                              9                                                             ([@b34-etm-0-0-8205])
  Njølstad (2013)    2                 0          2     1               2                     0                              7                                                             ([@b35-etm-0-0-8205])
  Matsuo (2013)      2                 0          2     1               2                     0                              7                                                             ([@b36-etm-0-0-8205])
  Gorelick (2009)    2                 0          2     2               2                     1                              9                                                             ([@b37-etm-0-0-8205])
  Lerner (2007)      2                 0          2     1               2                     1                              8                                                             ([@b38-etm-0-0-8205])
  Scholz (2000)      2                 0          2     1               2                     2                              9                                                             ([@b39-etm-0-0-8205])

ITT, intention to treat

A score of 1 to 6 indicated low quality, whereas a score of 7 to 12 indicated higher quality.

###### 

Subgroup analyses of the association between pre-treatment thrombocytosis and overall survival.

  Variable                                Number of studies   HR (95%)               Z      P-value   I^2^ (%)   P-value
  --------------------------------------- ------------------- ---------------------- ------ --------- ---------- ---------
  Year of publication                                                                                            
    2000--2014                            5                   2.916 (1.534--5.543)   3.26   0.001     56.9       0.055
    2015--2017                            5                   2.296 (1.002--5.262)   1.96   0.049     88.7       \<0.001
  Region                                                                                                         
    Asia                                  5                   2.207 (0.772--6.311)   1.48   0.140     89.0       \<0.001
    Europe                                2                   2.687 (0.823--8.774)   1.64   0.102     66.6       0.084
    America                               3                   2.874 (1.388--5.952)   2.84   0.004     73.4       0.023
  Number of cases                                                                                                
    \<150                                 5                   2.202 (1.388--3.492)   3.35   0.001     26.5       0.245
    \>150                                 5                   2.779 (1.041--7.420)   2.04   0.041     91.2       \<0.001
  Type of cancer                                                                                                 
    USPC                                  2                   2.078 (0.969--4.457)   1.88   0.060       2.1      0.312
    Endometrial cancer                    8                   2.598 (1.355--4.982)   2.88   0.004     86.0       \<0.001
  Analysis                                                                                                       
    Multivariate                          9                   1.733 (1.430--2.100)   5.61   \<0.001   50.9       0.038
    Single factor                         4                   1.886 (1.117--3.186)   2.37     0.018   63.8       0.040
  Platelet count cut-off (×10^3^/mm^3^)                                                                          
    ≥350                                  1                   1.367 (0.303--6.171)   0.41   0.684     --         --
    \>400                                 8                   2.771 (1.382--5.557)   2.87   0.004     85.7       \<0.001
    Continuous                            1                   1.714 (1.055--2.785)   2.18   0.030     --         --

Pooled analysis was performed by generic inverse variance. USPC, uterine serous papillary carcinoma; HR, hazard ratio; FIGO, International Federation of Gynecology and Obstetrics.
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